Four medical professional societies sounded the alarm together on August 21. In a press release, they call on lawmakers and the joint self-administration of statutory health insurance to come to the table and remedy the damage caused. This refers to the regulatory situation for medical cannabis, which since the GKV Contribution Rate Stabilization Act came into force on July 30 has descended into a series of contradictory interpretations. According to the associations‘ estimates, 60,000 to 80,000 patients are affected.
📑 Inhaltsverzeichnis
Who is speaking here, and why it matters
The statement is supported by the Professional Association of Physicians and Psychological Psychotherapists in Pain and Palliative Medicine in Germany (BVSD), the German Society for Pain Medicine, the German Pain Society, and the Interdisciplinary Society for Orthopedic, Trauma Surgery and General Pain Therapy (IGOST). This represents virtually the entire German pain medicine community behind the text.
This is remarkable because these associations rarely speak loudly in cannabis debates. They represent no cultivation companies or importers, but rather the physicians who ultimately issue prescriptions. When precisely they speak of damage caused, it is not a lobbying formula but a description of what is currently happening in medical practices.
The contradiction that everything hinges on
At its core, it comes down to a single question. The new law requires a six-month trial with a cannabis-containing finished pharmaceutical before a cannabis prescription can be reimbursed by health insurance. The dispute is whether this prerequisite always applies or only when an approved finished pharmaceutical actually exists for the specific condition.
On August 6, the Association of Statutory Health Insurance Physicians and the GKV Top Association jointly declared that the prerequisite applies only within approved indications. We detailed this clarification at the time. A few days later, the KBV reassessed the legal situation and has since taken the position that the finished pharmaceutical must always be used first in an initial prescription, even outside its approval. The GKV Top Association did not follow this reversal. A joint interpretation therefore does not currently exist, with the KBV pointing to an expected clarification by the Federal Health Ministry.
For practice, this is the worst of all possible scenarios. A physician issuing a prescription today does not know which of the two interpretations will apply in a later audit procedure. The specialist societies describe exactly this state as a legal vacuum in which patients, physicians, and pharmacies are equally uncertain.
What an off-label preliminary course means medically
The stricter interpretation has a consequence that has often been lost in the debate so far. It requires physicians to use an approved pharmaceutical outside its approved indication in order to subsequently prescribe a different therapy. Off-label use is not a standard path under German law but an exception with its own burden of justification and its own liability risk. Making it a mandatory step before reimbursement inverts the usual logic.
There is also the time factor. Six months in pain medicine is not an administrative detail but half a year of quality of life. How sustainable a multi-year cannabis therapy can be for chronic conditions is shown, for example, by the evaluation of a British patient registry for endometriosis. In any case, both sides of the interpretation share one common ground: the trial can be ended prematurely if the finished pharmaceutical does not work or is not tolerated. What must be documented so this is later recognized is, however, also unclear.
A conflict that has been building for weeks
The current dispute is not an accident but the continuation of a development. With the law from summer, the Bundestag removed flowers from statutory health insurance reimbursement and anchored the priority for finished pharmaceuticals. Legal challenges are already underway against this regulation, whose approaches we have detailed in our own analysis. What this means for individual patients was described by cannabis patient Kevin Anahid in our interview.
It is striking how asymmetrical the debate is. There is intensive dispute over prices, import quantities, and reimbursability. The question of what evidence actually exists for which indication is rarely addressed systematically. Other countries approach this differently; Canada, for example, pools its cannabis research in a government-funded consortium. In Germany, disputes over jurisdiction replace the building of knowledge.
What needs to happen now
The associations‘ demand is deliberately narrow. They call for no repeal of the law and no new reimbursement rule, but rather a clear joint interpretation. This is the smallest possible step, and it lies entirely in the hands of the institutions involved. It requires no new legislative process but rather an agreement between the Association of Statutory Health Insurance Physicians, the GKV Top Association, and the ministry.
Whether it comes about is open. The KBV changed its position once within two weeks, the GKV Top Association has not moved publicly, and the Federal Health Ministry has not yet taken a position. As long as this remains the case, practices and pharmacies manage uncertainty they did not create. For the 60,000 to 80,000 affected, every month without clarification is a month when ongoing therapy hangs on an interpretation question.
Frequently asked questions
Which associations stand behind the demand?
Four specialist societies in pain and palliative medicine: the BVSD, the German Society for Pain Medicine, the German Pain Society, and IGOST. They represent physicians who issue cannabis prescriptions in practice, not manufacturers or importers.
What exactly is unclear about the current regulation?
It is unclear whether the mandatory six-month trial with a cannabis-containing finished pharmaceutical always applies or only for conditions where such a product is approved. The Association of Statutory Health Insurance Physicians has taken the stricter interpretation since mid-August, and the GKV Top Association has not followed suit.
What does this mean for ongoing therapies?
The specialist societies speak of a legal vacuum for 60,000 to 80,000 people. Those affected currently do not know for certain in what form and at what cost their treatment can continue. A binding clarification is pending, so patients should seek discussion with their treating physician and their health insurance company.
Can the trial be discontinued?
Yes, both sides agree on this. If the finished pharmaceutical does not work or is not tolerated, the trial can be ended prematurely and switched to a cannabis extract or other cannabis medicine. What documentation is required for this is, however, also unclear.
Who could resolve the conflict?
A joint interpretation by the Association of Statutory Health Insurance Physicians and the GKV Top Association would suffice, if necessary flanked by a clarification from the Federal Health Ministry. A new legislative process would not be necessary.
Sources: Joint press release from BVSD, German Society for Pain Medicine, German Pain Society, and IGOST of August 21, 2026; Practice notice from the Association of Statutory Health Insurance Physicians of August 6, 2026; Deutsches Ärzteblatt on the KBV’s reassessment.
Sollten Krankenkassen Cannabis auf Rezept einfacher erstatten?
Note: This article reflects the status as of August 2026 and does not constitute medical advice. Whether cannabis therapy is appropriate in individual cases is decided by the treating physician. Questions about cost coverage should be clarified with the patient’s health insurance company.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
